Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stem Cell Therapeutics (SCT) has recruited first patient in an open label Phase IIa traumatic brain injury (TBI) drug NTx-428 trial entitled 'A Phase IIa, Single Center, Open Label Study to Characterize the Safety of Human Chorionic Gonadotrophin (hCG) and Epoeitin Alpha (EPO) in Traumatic Brain Injury.'
Subscribe to our email newsletter
The trial aims to characterize the safety profile of NTx-428 when administered to patients who have sustained a TBI.
The company expects to complete the recruitment of 10 patients by year end 2011.
SCT chairman of the Board Dean Peterson said SCT is excited to have enrolled its first TBI patient, reaffirming the board and management’s commitment to moving forward as a biotechnology company and adding value to its intellectual property portfolio.
"The board and SCT management are actively working on various initiatives and SCT continues to appreciate the ongoing support of its shareholders," Peterson said.